黃牛與荷蘭乳牛換毛期的研究

　　生物受到外在環境極大的影響，特別是身體表面，直接左右於外在環境的部分很多，與生理變化相同、形態上的變化也很顯著。覆蓋的毛髮掌管體溫調節與保護身體的功能，各種動物會依照品種，或者是個體，各自呈現著最適合各自生存環境的狀態。因此，熱帶地區的家畜與溫帶地區的家畜有所不同是極為理所當然的自然現象。與冷熱調節關係密切、依據季節轉變的覆蓋皮毛的換毛狀態亦是如此，不難想見溫帶地區的家畜、與熱帶地區的家畜身上顯現的差異性。本論文即為溫帶產乳牛Holstein與熱帶產牛的黃牛的換毛狀態比較調查。 　　研究內容如下所述。(1)換毛通常進行於春秋二季。不過，會因為品種的不同而有時期上的差異。Holstein在春天的5月開始換毛，秋天的話在10月以後才會開始。換毛最為明顯的時期是6月。黃牛的狀況是在春天的4月，秋天的9月開始換毛。4月中旬過後、以及9月底至10月初是換毛最為明顯的時期。這個換毛狀態也會因為不同個體而有些許的差異性。(2)除了春秋二季的定期換毛以外，每個月多少都會有一些換毛。將新生毛的比例加以平均的話，則可知Holstein在6月有34％，7月有12％，8月有31％的程度。黃牛則是在6月有12％，7月有16％，8月有26％這樣的程度。(3)只要換成夏毛的話，則其中不會混有冬毛。(4)覆蓋毛髮因應氣溫變化而有長度與粗細的不同，冬天細長，夏天粗短。(5) Holstein與黃牛互相比較，則換毛的顯著時期較遲。這是因為在因應氣候的方面，Holstein的反應程度比黃牛來得低。(6)一般而言，夏毛的生存期比冬毛短，夏毛在經過約略5個月之後轉為冬毛，而冬毛則是經過約略7個月後轉為夏毛。(7)髓質在夏天的時候不太發達。封面、書名頁、印記、目次頁 I　緒言 II　研究材料並ニ研究方法 　A）供試動物 　B）供試動物ノ飼養管理 　　i）黄牛ノ状態 　　ii）ホルスタインノ状態 　C）試驗期間及ビ採毛期日 　D）採毛方法 　E）調査方法 III　實驗結果 IV　實驗結果ノ觀察 　A）ホルスタイン 　B）黄牛 　C）ホルスタイント黄牛ノ比較 V　結論 VI　摘要 参【參】考文献 圖表 　（一） 　（二） 圖版、印記、封

Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study.

BACKGROUND Ribavirin is currently recommended for treating chronic hepatitis E virus (HEV) infection. This retrospective European multicenter study aimed to assess the sustained virological response (SVR) in a large cohort of solid organ transplant (SOT) recipients with chronic HEV infection treated with ribavirin monotherapy (N = 255), to identify the predictive factors for SVR, and to evaluate the impact of HEV RNA mutations on virological response. METHODS Data from 255 SOT recipients with chronic HEV infection from 30 European centers were analyzed. Ribavirin was given at the median dose of 600 (range, 29-1200) mg/day (mean, 8.6 ± 3.6 mg/kg/day) for a median duration of 3 (range, 0.25-18) months. RESULTS After a first course of ribavirin, the SVR rate was 81.2%. It increased to 89.8% when some patients were offered a second course of ribavirin. An increased lymphocyte count at the initiation of therapy was a predictive factor for SVR, while poor hematological tolerance of ribavirin requiring its dose reduction (28%) and blood transfusion (15.7%) were associated with more relapse after ribavirin cessation. Pretreatment HEV polymerase mutations and de novo mutations under ribavirin did not have a negative impact on HEV clearance. Anemia was the main adverse event. CONCLUSIONS This large-scale retrospective study confirms that ribavirin is highly efficient for treating chronic HEV infection in SOT recipients and shows that the predominant HEV RNA polymerase mutations found in this study do not affect the rate of HEV clearance.This large-scale retrospective study that included 255 solid organ transplant recipients confirms that ribavirin is highly efficient for treating chronic hepatitis E virus (HEV) infection and shows that HEV RNA polymerase mutations do not play a role in HEV clearance

Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study

International audienc